M. Bontenbal

4.9k citations

66 papers · 3.4k indexed · h-index 31

Oncology top 1%
Cancer Research top 1%
Genetics top 5%
Molecular Biology
Pulmonary and Respiratory Medicine top 5%

Co-authors: Jaap Verweij Jacques Bonneterre Carolien H. Smorenburg John A. Foekens J.G.M. Klijn Robert Paridaens Martine Piccart J. Benraadt
Topics: Cancer Treatment and Pharmacology (30 papers)Breast Cancer Treatment Studies (22 papers)HER2/EGFR in Cancer Research (14 papers)
Cited by: Cancer Research Oncology Dermatology
Journals: New England Journal of Medicine The Lancet Journal of Clinical Oncology
Partner nations: Netherlands United States Belgium

In The Last Decade

M. Bontenbal

66 papers receiving 3.2k citations

Peers

Countries citing papers authored by M. Bontenbal

Since Specialization

Citations

This map shows the geographic impact of M. Bontenbal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Bontenbal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Bontenbal more than expected).

Fields of papers citing papers by M. Bontenbal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Bontenbal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Bontenbal. The network helps show where M. Bontenbal may publish in the future.

Co-authorship network of co-authors of M. Bontenbal

This figure shows the co-authorship network connecting the top 25 collaborators of M. Bontenbal. A scholar is included among the top collaborators of M. Bontenbal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Bontenbal. M. Bontenbal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial 2011 ·Clinical Breast Cancer ·Paul Hamberg,Monique M.E.M. Bos,Hans J. Braun,Jacqueline M. Stouthard,(unknown),Frans Erdkamp,(unknown),M. Bontenbal,Geert-Jan Creemers,Johanneke E.A. Portielje,Hans Pruijt,O. J. L. Loosveld,Willem M. Smit,E.W. Muller,Paul Schmitz,Caroline Seynaeve,Jan G.M. Klijn	48
2	Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer 2011 ·Journal of Cancer Research and Clinical Oncology ·Marie‐Christine W. Gast,Marc Zapatka,Harm van Tinteren,M. Bontenbal,Paul N. Span,Vivianne C. G. Tjan‐Heijnen,Jaco C. Knol,Connie R. Jiménez,Jan H.M. Schellens,Jos H. Beijnen	10
3	Multimodality treatment for anaplastic thyroid carcinoma – Treatment outcome in 75 patients 2009 ·Radiotherapy and Oncology ·Annemarie T. Swaak‐Kragten,Johannes H.W. de Wilt,Paul Schmitz,M. Bontenbal,Peter C. Levendag	93
4	Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer 2008 ·Journal of Clinical Oncology ·Martine Piccart,Tomasz Burzykowski,Marc Buyse,George W. Sledge,James Carmichael,Hans‐Joachim Lück,John R. Mackey,Jean‐Marc Nabholtz,Robert Paridaens,Laura Biganzoli,Jacek Jassem,M. Bontenbal,Jacques Bonneterre,Stephen Chan,Gül Başaran,Patrick Therasse	164
5	Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients 2008 ·BMC Cancer ·Marie‐Christine W. Gast,Harm van Tinteren,M. Bontenbal,(unknown),M. Nooij,Sjoerd Rodenhuis,Paul N. Span,Vivianne C. G. Tjan‐Heijnen,Elisabeth G.E. de Vries,Nathan Harris,Jos W. R. Twisk,Jan H.M. Schellens,Jos H. Beijnen	24
6	Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy 2006 ·British Journal of Cancer ·Juliane Hannemann,Petra Kristel,Harm van Tinteren,M. Bontenbal,Q.G.C.M. van Hoesel,W. M. Smit,M. Nooij,Emile E. Voest,Elsken van der Wall,P. Hupperets,Elisabeth G.E. de Vries,Sjoerd Rodenhuis,Marc J. van de Vijver	54
7	CBO-richtlijn 'behandeling van het mammacarcinoom' 2002 ·Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank ·Emiel J. Rutgers,J.W.R. Nortier,M.K. Tuut,Geertjan van Tienhoven,H. Struikmans,M. Bontenbal,M.F. von Meyenfeldt,Gerard Vreugdenhil,(unknown),Bert Garssen,J.L. Peterse	38
8	Combination chemotherapy of the taxanes and antimetabolites 2001 ·European Journal of Cancer ·Carolien H. Smorenburg,Alex Sparreboom,M. Bontenbal,Jaap Verweij	52
9	Capecitabine in Breast Cancer: Current Status 2001 ·Clinical Breast Cancer ·Carolien H. Smorenburg,M. Bontenbal,Jaap Verweij	14
10	Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients 2000 ·Anti-Cancer Drugs ·Carolien H. Smorenburg,(unknown),M. Bontenbal,A.S.T. Planting,H. Sindermann,Jaap Verweij	55
11	Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam Symptom Checklist 2000 ·European Journal of Cancer ·(unknown),Desmond Curran,Martine Piccart,J.C.J.M. de Haes,P.F. Bruning,J.G.M. Klijn,M. Bontenbal,C van Pottelsberghe,M. Groenvold,Robert Paridaens	49
12	Uptake and distribution of doxorubicin in hormone-manipulated human breast cancer cells in vitro 1998 ·Breast Cancer Research and Treatment ·M. Bontenbal,Anieta M. Sieuwerts,Harry A. Peters,Wim L.J. van Putten,(unknown),Jan G.M. Klijn	5
13	Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer 1998 ·British Journal of Cancer ·(unknown),M. Bontenbal,Maria Andersson,J. Wildiers,Giorgio Cocconi,Jacek Jassem,Robert Paridaens,Nicole Rotmensz,Richard Sylvester,H.T. Mouridsen,J.G.M. Klijn,A. Van Oosterom	41
14	Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer 1996 ·Breast Cancer Research and Treatment ·Elisabeth G.E. de Vries,Sjoerd Rodenhuis,H. Schouten,P. Hupperets,Wil V. Dolsma,Joos V. Lebesque,G.H. Blijham,M. Bontenbal,Nanno H. Mulder	14
15	Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer 1994 ·British Journal of Cancer ·(unknown),Henk Portengen,(unknown),(unknown),Benoı̂t Thirion,M. Bontenbal,J.G.M. Klijn	47
16	Paclitaxel (Taxol) induces cumulative mild neurotoxicity 1994 ·European Journal of Cancer ·Joop van Gerven,(unknown),Martin J. van den Bent,M. Bontenbal,M.E.L. van der Burg,Jaap Verweij,(unknown)	66
17	Phase II study of carboplatin and etoposide as a first line regimen in patients with metastatic breast cancer 1994 ·Annals of Oncology ·Ate van der Gaast,M. Bontenbal,A.S.T. Planting,T.C. Kok,T. A. W. Splinter	6
18	Risk of endometrial cancer after tamoxifen treatment of breast cancer 1994 ·The Lancet ·Flora E. van Leeuwen,Alexandra W. van den Belt‐Dusebout,(unknown),J. Benraadt,(unknown),(unknown),J.W.W. Coebergh,Lambertus A. Kiemeney,Charles H. F. Gimbrère,R. Otter,Leo J. Schouten,Ronald Damhuis,M. Bontenbal	455
19	Growth Factors 1993 ·Annals of the New York Academy of Sciences ·J.G.M. Klijn,P.M.J.J. Berns,M. Bontenbal,John A. Foekens	9
20	Manipulation of cell cycle kinetics: Influence on the cytotoxicity of doxorubicin in human breast cancer cells 1990 ·The Journal of Steroid Biochemistry and Molecular Biology ·M. Bontenbal,Anieta M. Sieuwerts,Harm Peters,Pieter Sonneveld,J.A. Foekens,J.G.M. Klijn	11

About M. Bontenbal

M. Bontenbal is a scholar working on Oncology, Cancer Research and Dermatology, having authored 66 papers that have together received 3.4k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (30 papers), Breast Cancer Treatment Studies (22 papers) and HER2/EGFR in Cancer Research (14 papers). The work is most often cited by research in Cancer Research (1.2k citations), Oncology (2.1k citations) and Dermatology (228 citations). M. Bontenbal has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Jaap Verweij, Jacques Bonneterre, Carolien H. Smorenburg, John A. Foekens, J.G.M. Klijn, Robert Paridaens, Martine Piccart, J. Benraadt, Alexandra W. van den Belt‐Dusebout and Charles H. F. Gimbrère. Their work appears in journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact